<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-031085
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051007
<FILING-DATE>20051007
<DATE-OF-FILING-DATE-CHANGE>20051007
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051128507
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v026915-6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.26435 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a>
      <div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;October
                7, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>EXHIBIT
        INDEX</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  approved for US Medicare rebate.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v026915-ex99_1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.26435 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">EXHIBIT
      99.1</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg" alt=""><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
        RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7
        October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>
        approved for full US Medicare rebate </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Centers
        for Medicare &amp; Medicaid Services in the United States has designated the
        single-indication orphan drug Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        as
        eligible for Medicare pass-through payment under the Hospital Outpatient
        Prospective Payment System (OPPS) effective 1 October 2005. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        week, pSivida </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">entered
        into a definitive merger agreement to acquire </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
        Delivery Systems (CDS), a private US drug delivery company located in the
        Boston, Massachusetts area. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        was
        developed by CDS and global eye care health company, Bausch &amp; Lomb commenced
        marketing the product in the US in June.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        acquisition of CDS is expected to close in the fourth quarter of 2005 and
        is
        subject to Australian regulatory and pSivida shareholder approvals, as well
        as
        other customary closing conditions.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
        for Uveitis</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
        &amp; Lomb&#8217;s </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
        </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
        the
        world&#8217;s first intravireal drug implant for the treatment of this condition that
        affects an estimated 175,000 people in the United States and an estimated
        800,000 people worldwide. The product received FDA fast track status, designed
        to allow for priority review of novel therapies for serious diseases for
        which
        there is an unmet medical need. It also received FDA orphan drug designation
        for
        this indication. Control Delivery Systems anticipates receiving royalties
        from
        Bausch &amp; Lomb from this product this year and is presently priced at
        US$18,250 for a treatment period of 30 months.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        copy of
        the Bausch &amp; Lomb media release is attached.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-ENDS-</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 9 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow, PhD / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS
        Revenues</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
        Delivery Systems had unaudited revenues of US$8 million for the year ended
        30</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        June
        2005 which does not include Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        royalties as marketing of that product has only recently commenced by Bausch
        &amp; Lomb.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
        and animals. The IP portfolio consists of 29 patent families, 34 granted
        patents
        and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
        as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
        largest science and technology company in Europe. QinetiQ is the former UK
        government Defence Evaluation Research Agency and was instrumental in
        discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
        having access to its cutting edge research and development facilities. For
        more
        information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        announcement does not constitute an offer of any securities for sale or the
        solicitation of an offer to buy any securities. Any securities offered may
        not
        be or have not been registered under the US Securities Act of 1933, as amended,
        and may not be offered or sold in the United States absent registration or
        an
        applicable exemption from registration requirements."</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues, our inability to negotiate and
        consummate the proposed acquisition, our inability to successfully integrate
        the
        CDS&#8217;s operations and employees; the failure of the CDS&#8217;s products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        to
        achieve expected revenues and the combined entity&#8217;s inability to develop
        existing or proposed products. Other reasons are contained in cautionary
        statements in the Registration Statement on Form 20-F filed with the U.S.
        Securities and Exchange Commission, including, without limitation, under
        Item
        3.D, "Risk Factors" therein. We do not undertake to update any oral or written
        forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Bausch
        &amp; Lomb Announces Medicare Reimbursement Terms for
        Retisert(TM)</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>10/6/2005
        8:01:00 AM EST</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
        &amp; Lomb announced today that the Centers for Medicare &amp; Medicaid Services
        has designated the single-indication orphan drug Retisert(TM) (fluocinolone
        acetonide intravitreal implant), 0.59 mg, as eligible for Medicare pass-through
        payment under the Hospital Outpatient Prospective Payment System (OPPS)
        effective October 1. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        payment rate to hospitals billing for Retisert using HCPCS code C9225 is
        set at
        $19,345, as reported in the October 2005 update of OPPS Addendum A on the
        CMS
        website, http://www.cms.hhs.gov/providers/hopps. The payment methodology
        is
        based upon 106 percent of wholesale acquisition cost (WAC). Coding and payment
        amounts for non-Medicare procedures vary by insurer. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert
        was approved as a single-indication orphan drug by the U.S. Food and Drug
        Administration in April for the treatment of chronic noninfectious uveitis
        affecting the posterior segment of the eye, a sight-threatening inflammatory
        disease. Bausch &amp; Lomb launched Retisert in the U.S. in June. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        most
        common adverse events - which are anticipated given the nature of the disease
        and the type of drug used - include cataract progression, which is managed
        by
        standard cataract surgery; increased intraocular pressure, which is managed
        with
        the use of IOP-lowering eye drops or filtering surgery; and procedural
        complications and eye pain. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
        &amp; Lomb is the eye health company, dedicated to perfecting vision and
        enhancing life for consumers around the world. Its core businesses include
        soft
        and rigid gas permeable contact lenses and lens care products, and ophthalmic
        surgical and pharmaceutical products. The Bausch &amp; Lomb name is one of the
        best known and most respected healthcare brands in the world. Founded in
        1853,
        the Company is headquartered in Rochester, New York. Bausch &amp; Lomb's 2004
        revenues were $2.2 billion; it employs approximately 12,400 people worldwide
        and
        its products are available in more than 100 countries. More information about
        the Company can be found on the Bausch &amp; Lomb Web site at www.bausch.com.
        Copyright Bausch &amp; Lomb Incorporated. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TM/(R)
        denote trademarks of Bausch &amp; Lomb Incorporated</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0HV17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C`T(#`T.C$T
M.C`T``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```#T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)"`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!!?M$;MSMKVOCZ6Y0<SG]C'[A
MCQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW58E#=SRV0SU++';*,:G<?Y[)
MMJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4M?\`S=EE'^']/^9?^BL_2*\_
M]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8`Y>/N2D)WQ1,>*'!'@^;_"3P
MV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8V7N.5U%X;D6;6?2=C_8:_P#C
M/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]VZQUOH[7N]7]+7O]*S^;4Z^E
M8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PBL]3ZCC],P+L_)W&G';N?L&YT
M2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K:27-._Q@_5YK\>3?Z61$Y'I$
M55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRFAEAI99J^T>$@<_R)W.3.9SQP
M8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;CD8KQ+G/=)_L?2_\`(*=GV;]K
M5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.0\/S_I8Y^J.1?P^-Z6WDEF=.
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M-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?Z+O^Y'I(S?V1T#IE=9?5@X&*
MT,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".(WH:KJYG4:<FBFFJX5!K2\L-
M0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1N+CI['/^C[O[2HYN7E=7%;\/
M'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F4MCIC6,Q6UM98Q[6M%AM#MQ,
M?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^XXN-DX_2*&W7_O6U76VMC6-X
M:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M
M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=YD787HX^+F-)-C6D.(@-,;=W
MJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGAWTLC&=^?[&;_`/3?X;U%UN3B
M493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/THR6<O$@\4M+C$:?U0Y=8LZ=
MU&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2U6<7IF)BO]2MI+^SG&2)_=17
M8E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F,>>.+BE..'%CEQ2A&<FP9"_I
M5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;]&E__75<R.G_`+._Q8.H(BQ]
M-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`9RXU[7N9]/;O:=A&YKMC59ZE
MT[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5.$WDU'J!$/\`#^9X+ZQ3_P"-
MKTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"VQ'YJZBSZO]+MZ,WHEE9?A,:U
MC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-N)8VZNYUCB\N:6NK:]T_S5>S
MV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*>L55;LGJF4T'TF%K?;7LBZUV
MRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@!HL<+<G?:VMI<UGJ.]VQ;O5/
MJ=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C]FS]&K'2?JYTGHU^1?T^HTG)
M@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3]"/W7__1[#ZT_8_MF)'[2_:.
MRST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_S2^WU>IZO[:@>G^U_5^U=X^S
M?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209GZJ27RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]G_[0[P4&AO=&]S:&]P(#,N,``X
M0DE-!"4``````!``````````````````````.$))30/M```````0`$@````!
M``$`2`````$``3A"24T$)@``````#@`````````````_@```.$))300-````
M```$````>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`
M.$))300*```````!```X0DE-)Q````````H``0`````````!.$))30/U````
M``!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!
M`%H````&```````!`#4````!`"T````&```````!.$))30/X``````!P``#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z`````#_________
M____________________`^@``#A"24T$`````````@`!.$))300"```````$
M`````#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````-)````!@``````````````/0```-@````*`%4`;@!T
M`&D`=`!L`&4`9``M`#$````!``````````````````````````$`````````
M`````-@````]``````````````````````$`````````````````````````
M$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<````]`````%)G:'1L;VYG````V`````9S;&EC97-6;$QS`````4]B
M:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G
M<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X`
M```-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E````
M`$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@
M;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````/0````!2
M9VAT;&]N9P```-@````#=7)L5$585`````$```````!N=6QL5$585`````$`
M``````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E
M;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO
M<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)
M=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=```
M``MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N
M90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``````
M```,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG````
M```X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````"20`
M```!````@````"0```&````V````"0@`&``!_]C_X``02D9)1@`!`@$`2`!(
M``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"
M$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!
M!?M$;MSMKVOCZ6Y0<SG]C'[ACQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW
M58E#=SRV0SU++';*,:G<?Y[)MJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4
MM?\`S=EE'^']/^9?^BL_2*\_]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8
M`Y>/N2D)WQ1,>*'!'@^;_"3PV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8
MV7N.5U%X;D6;6?2=C_8:_P#C/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]
MVZQUOH[7N]7]+7O]*S^;4Z^E8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PB
ML]3ZCC],P+L_)W&G';N?L&YT2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K
M:27-._Q@_5YK\>3?Z61$Y'I$55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRF
MAEAI99J^T>$@<_R)W.3.9SQP8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;C
MD8KQ+G/=)_L?2_\`(*=GV;]K5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.
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MSOH_]J;/4_06_HOTEGK5UF^L-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?
MZ+O^Y'I(S?V1T#IE=9?5@X&*T,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".
M(WH:KJYG4:<FBFFJX5!K2\L-0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1
MN+CI['/^C[O[2HYN7E=7%;\/'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F
M4MCIC6,Q6UM98Q[6M%AM#MQ,?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^
MXXN-DX_2*&W7_O6U76VMC6-X:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3
MCUONM?6`RNMI<YQW-^BQON<M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=
MYD787HX^+F-)-C6D.(@-,;=WJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGA
MWTLC&=^?[&;_`/3?X;U%UN3B493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/
MTHR6<O$@\4M+C$:?U0Y=8LZ=U&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2
MU6<7IF)BO]2MI+^SG&2)_=178E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F
M,>>.+BE..'%CEQ2A&<FP9"_I5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;
M]&E__75<R.G_`+._Q8.H(BQ]-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`
M9RXU[7N9]/;O:=A&YKMC59ZET[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5
M.$WDU'J!$/\`#^9X+ZQ3_P"-KTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"V
MQ'YJZBSZO]+MZ,WHEE9?A,:UC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-
MN)8VZNYUCB\N:6NK:]T_S5>SV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*
M>L55;LGJF4T'TF%K?;7LBZUVRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@
M!HL<+<G?:VMI<UGJ.]VQ;O5/J=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C
M]FS]&K'2?JYTGHU^1?T^HTG)@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3
M]"/W7__1[#ZT_8_MF)'[2_:.RST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_
MS2^WU>IZO[:@>G^U_5^U=X^S?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]DX
M0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N
M`#`````!`#A"24T$!@``````!P`!`````0$`_^$22&AT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E
M<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G
M('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU
M)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U
M=6ED.C9E,&(S86(W+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8R<*("!X
M;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^
M"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C9E
M,&(S86(U+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8SPO>&%P34TZ1&]C
M=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z
M>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_[@`.061O8F4`9(`````!
M_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``]`-@#`2(``A$!`Q$!_]T`!``._\0!/P```04!`0$!`0$`````````
M`P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$
M`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$
M`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U
M5)),3`)\$E+I*G7U3%>X-.ZLNT&]I:#\U8NOJHK]2UVU@TGXJ*',89QE..2)
MC'YC?R?WOW4T>R1)4_VM@?Z7\#_<A974R^HU]-?4_+>8K%VYK)/[VQKG)HYO
MEB0!FQDG0>N*B"!='[&WE9>+ATNR,JUM-+/I/>0!^*Q&]>ZIU4EO0<2,?C]H
M9DLJ/\JBD?IKDU?U?I:]O4/K)D_M#*:996X1CUG]VC&_._KO6SCYM%Q+*VN8
M&-F7-VM@*0YL49C&9Q]P[0OU?XK'626I]$?^=]OZ+S/6[OK1T2BC/?U)F8Y]
MS*G8GHM8UV\_1K<#ZBZX20"=#X+GZ:7]?ZM7U*P1TKI[C]A:?\-;]%^7_P`3
M7]''_P"W%T*D*,8UD03PGY;/%_A>I2222#(I))#=D8[3#K6-/@7`(2E&.LB(
M^9I21),US7"6D$'N-5&VUE3#98=K&\E(R`!D2!$"[Z5W4S20J,FC(!-+]X;H
M45",XSB)1(E$[2B>**E))(>1?5C469%SME532^QQ[-:-SBG*2)+/Z9U[I/57
MO9T_(%[J@'/`#A`/'TVM6@D@$$6""/!22A9;74PV6O;6P<N<0`/[3DU.1CW@
MFBUEH;H2QP='QVI)OHD22224I))))3__T/54DDDE.3U>L.+M)]L@^\Q']7]$
MK'3;Q9T\.N(BN0YSN(;^<Z?Y*;J51)#APX%O#S^%1VK&=TQ_5::^FW9#L;'9
M87Y5#?:ZYA`V5;OS6[Q^D61#]7\3/%48YHRC_>E_.0XOZZ^1/MV!Q$=&74+*
M;<DVXY:ZFQK7L<W@@CZ06MT9C/L37;1NW.UC7E974::J,GT*6AE53&,K8.`T
M-AK0M;I#FMZ>'.(#0723\54Y`1_TKS.@H>[]/UD5TK]N-[Z-+J#C?U+TW:LJ
M&C8<1Q)_F_<KXQ6Y6$RFPGTG_P`ZT%TN$_S9-GZ38[\]9@)OS+LAH.QQ(:8>
M0>W^"A;M+-E36=P`#S_W[W*Y\,N>?F,VA$Y2J7Z7#Q?J_P#!X8+<@'"`R:UK
M&AC`&M:(:T:``=@AY.5CXE#\C)L;536)?8XP`.-458?UU_\`$OG_`-1O_5L6
ML-V*9X8RD/T03]C<9U_HK\5^8W,J.-6[8^W<-H=&[9_63].Z[TCJA<W`RF7O
M9JY@,.`\=CMKEP/U%^K^!UIF4>H;[*L9S?3I#BUFYX.ZQVW\_P!BI8M7[$^N
M]>-C..RG*%0)Y-=D-V._L/3N$:CLU1S.3AQS,1P3/#OZGTKK.393CM96=KK#
M!(Y@<JAA=).50;C9MDD-$3Q^\M7J&&,NC8#M>TRP^?@L:N[.Z;86D%H/+':M
M/P7/?$8"/.C+S4)9.4,>&/#?#CEX\+HP^6HFI)NGLSL7+](,<ZO=MLCZ/]<+
M7RV4OQWMO=LK(]SIB-4'!ZE3E^WZ%HU+#W_JI^J?T"[X#\H5SEH8L7(Y3BR?
M>,7#.<1/Y8CA_FO^^6DDR%BBMTZK#J:\8MGJ`D;C,P5#'Z]T;*R1B8^959D$
MD"IKO=+?IZ?R4'H'\U=_6'Y%P756?L+Z]B]OMJ-[+Q_4M_G?^JL5GX;(9.5Q
MR$1CL&H0^6/JDP<SD.(@[@R$9$^+Z3G=2P.G5MLSKV8['G:USS`)YA!NR.F=
M2Z1?9Z[78%M;VV7L.@;!;8X/_DKB?\9V8;,[#P&&?38;2T?O6'8S_HL73W8(
MZ?\`4RW#`@TX3P[^L6.=9_TRKE:`]UGNF4\D:'#C'_.[(/JGTWZM85^0[HN8
M<JQ[&BT%X?#03M/M:Q;F=U'!Z?3Z^;<RBJ8#GF)/@W]Y<'_BM_IF?_Q5?_5.
M0/\`&7DVV=:HQI/ITTAS6]MSW.W._P"BU*KE3''/P<N,@B!K0B/EW>A^M75^
MF=4^JF<[!R&9`:&;FM/N'O9])CO<J7^*T`86?_QK/^I5?ZP_4[I73?JT<W'W
MMRZ6,]2S<2+-Q:UX>SZ.WW*S_BN_H6?_`,:S_J4=.$UW6@S/-8^,`'@/R[?I
M/79W4L#I]8LS<BO'8>"]P$_U1])RIXGUI^K^9:*:,ZIUCC#6DEI)_D^IM7-]
M7^I76>L=>?F9E]8PG/AH:XE[*1PUC2W9O6#]<NC=#Z7;CMZ5?O>[<+Z=XL+2
MV-C]/H;D``>J_)GRPXI<`$(FO4?5+^Z^KI+)^JN5=E_5[!OO=OL=4`YQY.TE
MDG_-20K6FQQC@X^G#Q/_T?55%[V5L=98X-8P%SG'0`#DE27*]=NNZ]U<?5O$
M>68E(%O5+F\[>68S3_+2"V<^$=R=(CO))@9O4?K%U/[7CO=C="Q2YC=(.4[Z
M+IG_``#5J6]$H>[<RQ[#VD[OR^Y7L?'IQJ&8]#!754T-8QN@`"(H<_+8,]>[
MC$ZV_>_QHIQ\4!\UDZR>7S:#CY+JB\V$`>X\ZA6\'I8RL<6.M<UI)&P<:%4^
MMY3&]4=CU`WY3@"W'KU=$?2?^;57_P`)8M3HN/<<9K\BQKH)VU5_0:9[O/NN
M=_+^@L+E/A\9<[F&3'^HO(,8D3'CX9_HZ\>2,66630")N6EU^CYMO%Z=1BG<
MTN<X<%QX^#?HJTDDN@Q8L>*(ACB(1'2*PDG=2Q/KK_XE\_\`J-_ZMBVUB?77
M_P`2^?\`U&_]6Q2#<,>7^;G_`'9?DX'^*W^8ZC_7J_(]8?4??_C`.W7]>K&G
MD62I?4_HF;U+'S+^G9K\',H<QK'-)#'-<'$MLV^[LM[ZM_4/+PNJ,ZEU2YEC
MZ7%]=;"7%SS_`(2RQX:GF@26C",\F+#`1T$N+CZ5;U>?GC##9K+]\P08&B?'
MNHZAC2]H,Z/8=8*)DXU>34:K.#J".0?%9+NB9;''TK&EI[R6F/.%D\S/G<><
MRCC^\\M.->T.$2A+_NG4CPD;T>[5(%'4-M!D,L`8?FMOJG]`N^`_*$#!Z.W'
ML%MSM[V_1`X!\5;S*'9&,^EI`+QH3QRH>2Y/-CY7FA*/!+.)G'A!O@],N$)E
M(&4?#JT>@?S5W]8?D7+_`.-#`]N'U%HX+J+#\?TE7_HQ=ATW!LPV/:]P=O((
MCR0/K)T<]9Z1=@M<UECMKJGNX#FG=V5[X9CGBY7%#(.&40>*/^%)@YJ'N0F!
MK>WF'SKI3K?K'];,1]PD#TS8#K[:&-W?Y[F?]->D_6#_`)"ZA_X6M_ZARQ/J
MC]3LCH69=EY5M=SWUBNOTP=).Y_TOZK5T/4\5^9T[*Q*R&OOJ?6USN`7-+9*
MN2(L5T8<&*<<4^(>N=DO"_XK?Z9G_P#%5_\`5.5+_&."WZQM<>/0K/W%ZZCZ
MG_5/,Z!?DVY-U=HO8UK17.A:2==WQ4_KA]47=>]+(QK&U9=(+/?.U["=VUQ;
M]':Y&QQ6Q>QD/*B%>L'BX?JS^N;FN^J&0YIEKF5$'Q!<Q97^*[^A9_\`QK/^
MI4*?J'UF_I[L?J742\5L+<3&#G&ICOS7V$Q]#]S8MKZG_5S*Z!CY-63:RTWO
M:YIKG0`;==R&E$6OC')+/#(8&($:>6ZAUGJWUJZ[^Q\&\XN$7N8T`D2UD^I=
M;M]S_H^VI5_KC]6NG=!Q<)F*YS[[G/\`6L>=7`!NWV#VL;JM+._Q>]5JZF[+
MZ/E,K87FRLN+F/K+C.W<QKMRGG?XN^IY=;+KNH_:,]Q/K67;BP-_-95])WTD
M;&FNC#+%EE'()8S+(3I,G01_J/1?4O\`\3&!_4/_`%;TE:^K_3KNE]'QL"YS
M7V4-+7.9,&7.=IN_K))O7ZMSA/L\->K@JO'A?__2]-SLVC!Q795YVU,+0YW8
M;G!DG_.5+HG26]-=G7FUMQSLAV1ZO?8[Z#''_@_<C];_`&=^R<K]I_T+TSZW
M,Q_)C\_=]!>=4#ZI;1N=U@XG8$`5Q\:W%$;,4^(3C41+]VY<)XOTGN^I_6SH
M?33LLR!=?PW'H_2/)_=VL^C_`&E2KL^M'73.T]#Z<[OH[*>/*?;CHGU;_P"9
MT#]B>AZL:S_/?/UOTRZ%+3HGAG+YY4/W8?MFXE7U=&-4:,1S:JW&;#JZRP_O
MY%SO?:Y6\/"S<7:P7,-0,ENW7S@K025'[KR_WCCXY?>*NO=E[G!_<XOYMEC+
MT`1`X.E#TJ2225U"EG]>Z:_JO2<G`K>*WWM#0]PD"'-=V_JK0221(`Q(EM6O
MD\]]4?JS?]7Z\EEU[+_M#F.!8"(VAP_._K+H4DD3=ZK<8@(`0UCTH\2DDDD%
AZDDDDE*22224I))))2DDDDE*22224I))))2DDDDE/__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
